Orexigen Therapeutics volatility elevated into PDUFA Orexigen Therapeutics June call option implied volatility is at 164, July is at 116, October is at 88; compared to its 26-week average of 81 according to Track Data, suggesting large movement into the PDUFA goal date of June 10 for Contrave.
Orexigen announces allowance of new U.S. patent for Contrave Orexigen Therapeutics announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 11/757,773, which covers use of Orexigen's sustained release formulation of naltrexone, which was designed to improve drug tolerability for Contrave in a method for treating obesity. The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the FDA.